AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TXG · NASDAQ · Biotechnology

10x Genomics (TXG)

Builds Chromium, Visium, Xenium, and Atera platforms for single-cell and spatial biology.

$80.70

After hours0.00 (0.00%)

At close$80.70(+2.02%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	154	184	141	153	152	165	155	173	149	166	151	151
Cost of revenue	58	68	48	49	45	54	49	48	49	53	45	39
Gross profit	96	116	93	104	106	111	105	125	100	113	106	112
	190	171	154	146	148	161	145	95	133	133	123	132
Research & development	108	65	69	63	66	67	64	61	57	56	57	57
	82	86	86	83	82	94	90	74	75	77	66	79
Selling & marketing	0	0	0	0	0	4	0	0	0	0	0	0
General & administrative	0	0	0	0	0	90	0	0	0	0	0	0
Other expenses	0	20	0	0	0	0	−9	−41	0	0	0	−3
Operating income	−95	−55	−61	−42	−41	−50	−39	30	−32	−20	−17	−20
	3	9	4	5	7	1	6	7	4	4	4	1
Interest income	4	5	5	5	5	4	4	4	5	5	5	5
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	−3	−9	−4	−5	−7	−1	−6	−7	−4	−71	−4	−1
Income before tax	−92	−47	−58	−37	−34	−48	−34	37	−28	−15	−13	−19
Income tax expense	1	2	2	1	1	1	1	2	−1	1	1	−1
Net income from continuing operations	−93	−49	−60	−38	−36	−49	−34	35	−27	−16	−13	−18
Net income	−93	−49	−60	−38	−36	−49	−34	35	−27	−16	−13	−18
EPS, basic	−$0.79	−$0.41	−$0.50	−$0.32	−$0.30	−$0.40	−$0.28	$0.28	−$0.22	−$0.13	−$0.10	−$0.14
EPS, diluted	−$0.79	−$0.41	−$0.50	−$0.32	−$0.30	−$0.40	−$0.28	$0.28	−$0.22	−$0.13	−$0.10	−$0.14
Weighted average shares, basic	118	119	119	120	121	122	123	124	126	127	128	130
Weighted average shares, diluted	118	119	119	120	121	122	123	125	126	127	128	130
EBITDA	−80	−35	−46	−26	−24	−38	−24	47	−16	64	−1	−19
Depreciation & amortization	11	12	11	11	11	11	10	10	12	12	12	0
EBIT	−92	−47	−58	−37	−34	−48	−34	37	−28	51	−13	−19